NeoScorch HN: Chemotherapy and Toripalimab for Head and Neck Cancer
This study, called NeoScorch HN, is looking at a new way to treat advanced head and neck cancers, including those in the oral cavity, oropharynx, and larynx. It combines standard chemotherapy with a drug called Toripalimab, which is an immunotherapy (a treatment that uses your body's own immune system to fight cancer). The goal is to see if this combination can help reduce the amount of surgery needed. Researchers will measure how well the treatment shrinks the tumor before surgery. You may be eligible if you have newly diagnosed, advanced head and neck cancer that can be treated with the goal of cure, and meet specific HPV testing requirements. This study is currently unclear on its recruitment status and plans to enroll 75 patients.
- Study design
- This is a Phase II interventional study with 75 participants across three groups. It is a single-institution, multisite trial.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 5 years to measure the major pathological response (how much cancer is gone after treatment).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Nyall R London, MD, Ph.D · PRINCIPAL_INVESTIGATOR · Otolaryngology - Broadway
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Major Pathological Response (MPR)Up to 5 years
The objective is to achieve high-quality or "deep" responses to treatment (measurable pathologic response, MPR) that are sufficient to enable surgical de-escalation (less extensive surgery) or response-adaptive, function-preserving surgery (tailoring the surgical approach to preserve organ structure and function while maintaining oncologic safety).